Cowen & Co. Keeps a Buy Rating on Neurocrine

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Neurocrine (NASDAQ: NBIX) today and set a price target of $100. The company’s shares opened today at $83.59.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 11.3% and a 49.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.

Currently, the analyst consensus on Neurocrine is Strong Buy and the average price target is $107.20, representing a 28.2% upside.

In a report issued on April 23, Jefferies also maintained a Buy rating on the stock with a $105 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $92.98 and a one-year low of $41.76. Currently, Neurocrine has an average volume of 802.6K.

Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NBIX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W.